Skip to main content

dostarlimab (Jemperli®)


Status: In progress

For the off-label treatment of locally advanced treatment-naive stage II/III deficient mismatch repair (dMMR) / high microsatellite instability (MSI-H) rectal cancer.

Medicine details

Medicine name dostarlimab (Jemperli®)
Formulation 500 mg concentrate for solution for infusion
Reference number OW26

As above

Company GlaxoSmithKline UK
BNF chapter Malignant disease & immunosuppression
Submission type One Wales
Status In progress
AWMSG meeting date 11/07/2023
Date of issue TBA
Follow AWTTC: